Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press29410.17650/2222-1468-2017-7-3-96-102REVIEWОБЗОРНАЯ СТАТЬЯTARGET THERAPY OF HIGH DIFFERENTIATED CARCINOMA RESISTANT TO RADIOIOD THERAPY (REVIEW OF LITERATURE)ТАРГЕТНАЯ ТЕРАПИЯ ВЫСОКОДИФФЕРЕНЦИРОВАННОГО РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ, РЕЗИСТЕНТНОГО К РАДИОАКТИВНОМУ ЙОДУ (ОБЗОР ЛИТЕРАТУРЫ)VasilkovS. V.ВасильковС. В.
Russian Federation

4 Koroleva St., Obninsk 249036.

Сергей Валерьевич Васильков. 

 249036 Обнинск, ул. Королева, 4. 

vsv003@mail.ruIsaevA. P.ИсаевП. А.
Russian Federation

4 Koroleva St., Obninsk 249036.

249036 Обнинск, ул. Королева, 4.

PimenovaI. S.ПимоноваИ. С.
Russian Federation

4 Koroleva St., Obninsk 249036.

249036 Обнинск, ул. Королева, 4.

IlyinA. A.ИльинА. А.
Russian Federation

4 Koroleva St., Obninsk 249036.

249036 Обнинск, ул. Королева, 4.

SevryukovF. E.СеврюковФ. Е.
Russian Federation

4 Koroleva St., Obninsk 249036.

249036 Обнинск, ул. Королева, 4.

A. F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiology Center, Ministry of Health of Russia.Медицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России.0711201773961020811201708112017Copyright ©; 2017, Vasilkov S.V., Isaev A.P., Pimenova I.S., Ilyin A.A., Sevryukov F.E.Copyright ©; 2017, Васильков С.В., Исаев П.А., Пимонова И.С., Ильин А.А., Севрюков Ф.Е.2017Vasilkov S.V., Isaev A.P., Pimenova I.S., Ilyin A.A., Sevryukov F.E.Васильков С.В., Исаев П.А., Пимонова И.С., Ильин А.А., Севрюков Ф.Е.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/294

Highly differentiated thyroid cancer refers to the non-aggressive tumors due to the fact, that it can grow slowly and does not metastasize into surrounding tissues and organs. Modern medicine has the ability to cope with this disease, identify it in the early stages and begin timely treatment, which includes surgery and subsequent radioiodine therapy according to the indications. At the same time, the resistance of distant metastases to radioiodine therapy in patients with highly differentiated thyroid cancer significantly worsens the survival prognosis. Results of the use of chemotherapy do not allow recommend it as a therapy of choice. Today the achievements of antitumoral drug treatment are mainly related to the development of targeted therapy, namely, using individual tyrosine kinase inhibitors, in particular Sorafenib, which became the first registered in Russia drug, proved its therapeutic effectiveness in patients with this pathology, whose treatment options are currently extremely limited or absent.

Высокодифференцированный рак щитовидной железы (ВДРЩЖ) относят к неагрессивным опухолям из-за того, что он долгое время способен не увеличиваться и не метастазировать в окружающие ткани и органы. Современная медицина имеет возможность справиться с этим заболеванием, выявив его на ранних стадиях и начав своевременное лечение, которое включает операцию и последующую радиойодтерапию по показаниям. В то же время резистентность отдаленных метастазов к терапии радиоактивным йодом у больных ВДРЩЖ значительно ухудшает прогноз выживаемости. Результаты применения химиопрепаратов не позволили рекомендовать их в качестве терапии выбора. Сегодня достижения противоопухолевого лекарственного лечения связаны, главным образом, с развитием таргетной терапии, а именно с применением отдельных ингибиторов тирозинкиназ, в частности Сорафениба. Он стал первым зарегистрированным в России препаратом, доказавшим свою терапевтическую эффективность у пациентов с данной патологией, возможности лечения которых в настоящее время крайне ограничены или отсутствуют.

highly differentiated thyroid cancerradioiodresistancetargeted therapyвысокодифференцированный рак щитовидной железырадиойодрезистентностьтаргетная терапия1. O’Neill C. J., Oucharek J., Learoyd D., Sidhu S. B. Standard and emerging therapies for metastatic differentiated thyroid cancer. The Oncologist 2010;15:146–56. PMCID: PMC3227939.O’Neill C. J., Oucharek J., Learoyd D., Sidhu S. B. Standard and emerging therapies for metastatic differentiated thyroid cancer. The Oncologist 2010;15:146–56. PMCID: PMC3227939.2. Kilfoy B. A., Zheng T., Holford T. R. et al. International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control 2009;20:525–31. DOI: 10.1007/s10552-008-9260-4. PMCID: PMC2788231.Kilfoy B. A., Zheng T., Holford T. R. et al. International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control 2009;20:525–31. DOI: 10.1007/s10552-008-9260-4. PMCID: PMC2788231.3. Altekruse S. F., Kosary C. L., Krapcho M. et al. SEER Cancer Statistics Review, 1975–2007. National Cancer Institute: Bethesda, MD, 2010.Altekruse S. F., Kosary C. L., Krapcho M. et al. SEER Cancer Statistics Review, 1975–2007. National Cancer Institute: Bethesda, MD, 2010.4. Gilliland F. D., Hunt W. C., Morris D. M. et al. Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 1997;79:564–73. PMID: 9028369.Gilliland F. D., Hunt W. C., Morris D. M. et al. Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 1997;79:564–73. PMID: 9028369.5. Петрова Г. В., Каприн А. Д., Грецова О. П., Старинский В. В. Злокачественные новообразования в России: обзор статистической информации за 1993–2013 гг. Под общей ред. А. Д. Каприна, В. В. Старинского. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2015. С. 464–80. [Petrova G. V., Kaprin A. D., Gretsova O. P., Starinskiy V. V. Malignant neoplasms in Russia. Review of statistical information for 1993 to 2013. By eds.: A. D. Kaprin, V. V. Starinskiy. Moscow: P. A. Herzen Moscow Scientific and Research Oncological Institute, 2015. Pp. 69, 81. (In Russ.)].Петрова Г. В., Каприн А. Д., Грецова О. П., Старинский В. В. Злокачественные новообразования в России: обзор статистической информации за 1993–2013 гг. Под общей ред. А. Д. Каприна, В. В. Старинского. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2015. С. 464–80. [Petrova G. V., Kaprin A. D., Gretsova O. P., Starinskiy V. V. Malignant neoplasms in Russia. Review of statistical information for 1993 to 2013. By eds.: A. D. Kaprin, V. V. Starinskiy. Moscow: P. A. Herzen Moscow Scientific and Research Oncological Institute, 2015. Pp. 69, 81. (In Russ.)].6. Altekruse S. F., Kosary C. L., Krapcho M. et al. SEER Cancer Statistics Review, 1975–2007. National Cancer Institute: Bethesda, MD, 2010.Altekruse S. F., Kosary C. L., Krapcho M. et al. SEER Cancer Statistics Review, 1975–2007. National Cancer Institute: Bethesda, MD, 2010.7. Radio-iodine halts one type of cancer. Life Magazine 1949; October 31: 54–6.Radio-iodine halts one type of cancer. Life Magazine 1949; October 31: 54–6.8. Trunnell J. B. The treatment of human thyroid disease with radioactive iodine. Trans N Y Acad Sci 1949;11(6):195–201. PMID: 18150148.Trunnell J. B. The treatment of human thyroid disease with radioactive iodine. Trans N Y Acad Sci 1949;11(6):195–201. PMID: 18150148.9. Maloof F., Vickery A. L., Rapp B. An evaluation of various factors influencing the treatment of metastatic thyroid carcinoma with I 131. J Clin Endocrinol Metab 1956;16:1–27. DOI: 10.1210/jcem-16-1-1. PMID: 13278379.Maloof F., Vickery A. L., Rapp B. An evaluation of various factors influencing the treatment of metastatic thyroid carcinoma with I 131. J Clin Endocrinol Metab 1956;16:1–27. DOI: 10.1210/jcem-16-1-1. PMID: 13278379.10. Ronga G., Filesi M., Montesano T. et al. Lung metastases from differentiated thyroid carcinoma. A 40 years’ experience. Q J Nucl Med Mol Imaging 2004;48:12–9. PMID: 15194999.Ronga G., Filesi M., Montesano T. et al. Lung metastases from differentiated thyroid carcinoma. A 40 years’ experience. Q J Nucl Med Mol Imaging 2004;48:12–9. PMID: 15194999.11. Sherman S. I. Target therapy of thyroid cancer. Biochem Pharmacol 2010;80(5):592–601. DOI: 10.1016/j.bcp.2010.05.003. PMID: 20471374.Sherman S. I. Target therapy of thyroid cancer. Biochem Pharmacol 2010;80(5):592–601. DOI: 10.1016/j.bcp.2010.05.003. PMID: 20471374.12. Chougent C., Brassard M., Leboulleux S. et al. Molecular targeted therapies for patients with refractory thyroid cancer. Clin Oncol (R Coll Radiol) 2010;22(6):448–55. DOI: 10.1016/j.clon.2010.04.008. PMID: 20554167.Chougent C., Brassard M., Leboulleux S. et al. Molecular targeted therapies for patients with refractory thyroid cancer. Clin Oncol (R Coll Radiol) 2010;22(6):448–55. DOI: 10.1016/j.clon.2010.04.008. PMID: 20554167.13. Licitra L., Locati L. D., Greco A. et al. Multikinase inhibitors in thyroid cancer. Eur J Cancer. 2010;46(6):1012–8. DOI: 10.1016/j.ejca.2010.01.010. PMID: 20171085.Licitra L., Locati L. D., Greco A. et al. Multikinase inhibitors in thyroid cancer. Eur J Cancer. 2010;46(6):1012–8. DOI: 10.1016/j.ejca.2010.01.010. PMID: 20171085.14. Kondo T., Ezzat S., Asa S. L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292–306. DOI: 10.1038/nrc1836. PMID: 16557281.Kondo T., Ezzat S., Asa S. L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292–306. DOI: 10.1038/nrc1836. PMID: 16557281.15. Roman S., Lin R., Sosa J. A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134–42. DOI: 10.1002/cncr.22244. PMID: 17019736.Roman S., Lin R., Sosa J. A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134–42. DOI: 10.1002/cncr.22244. PMID: 17019736.16. Sherman S. I. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010;22:464–8. DOI: 10.1016/j.clon.2010.03.014. PMID: 20452757.Sherman S. I. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010;22:464–8. DOI: 10.1016/j.clon.2010.03.014. PMID: 20452757.17. American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper D. S., Doherty G. M., Haugen B. R. et al. Revised American Thyroid Association Guidelines management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;9(11):1167–214. DOI: 10.1089/thy.2009.0110. PMID: 19860577.American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper D. S., Doherty G. M., Haugen B. R. et al. Revised American Thyroid Association Guidelines management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;9(11):1167–214. DOI: 10.1089/thy.2009.0110. PMID: 19860577.18. Segev D. L., Umbricht C., Zeiger M. A. Mollecular pathogenesis of thyroid cancer. Surg Oncol 2003;12:69–90. PMID: 12946479.Segev D. L., Umbricht C., Zeiger M. A. Mollecular pathogenesis of thyroid cancer. Surg Oncol 2003;12:69–90. PMID: 12946479.19. Pierotti M. A., Santoro M., Jenkins R. B. et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci USA 1992;89:1616–20. PMID: 1542652.Pierotti M. A., Santoro M., Jenkins R. B. et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci USA 1992;89:1616–20. PMID: 1542652.20. Salassidis K., Bruch J., Zizelsberger H. et al. Translocation t(10;14)(q11.2:q22.1) fusing the kinetin to the RET gene creates a novel rearranged from(PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma. Cancer Res 2000;60:2786–9. PMID: 10850414.Salassidis K., Bruch J., Zizelsberger H. et al. Translocation t(10;14)(q11.2:q22.1) fusing the kinetin to the RET gene creates a novel rearranged from(PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma. Cancer Res 2000;60:2786–9. PMID: 10850414.21. Fagin J. A. Molecular genetics of human thyroid neoplasm. Annu Rev Med 1994;45:45–52. DOI: 10.1146/annurev. med.45.1.45. PMID: 8198395.Fagin J. A. Molecular genetics of human thyroid neoplasm. Annu Rev Med 1994;45:45–52. DOI: 10.1146/annurev. med.45.1.45. PMID: 8198395.22. Santoro M., Carlomagno F., Hay I. D. et al. Ret oncogene activation in human thyroid neoplasms in restricted to the papillary cancer subtype. J Clin Invest 1992;89:1517–22. DOI: 10.1172/JCI115743. PMID: 1569189.Santoro M., Carlomagno F., Hay I. D. et al. Ret oncogene activation in human thyroid neoplasms in restricted to the papillary cancer subtype. J Clin Invest 1992;89:1517–22. DOI: 10.1172/JCI115743. PMID: 1569189.23. Ishizaka Y., Kobayashi S., Ushijima Т. et al. Direction of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene 1991;6(9):1667–72. PMID: 1717926.Ishizaka Y., Kobayashi S., Ushijima Т. et al. Direction of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene 1991;6(9):1667–72. PMID: 1717926.24. Jhiang S. M., Caruso D. R., Gilmore E. et al. Detection of the PTC/retTPC oncogene in human thyroid cancer. Oncogene 1992;7:1331–7. PMID: 1620547.Jhiang S. M., Caruso D. R., Gilmore E. et al. Detection of the PTC/retTPC oncogene in human thyroid cancer. Oncogene 1992;7:1331–7. PMID: 1620547.25. Mitsutake N., Knauf J. A., Mitsutake S. et al. Conditional BRAFV600E expression induced DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 2005;65:2465–73. DOI: 10.1158/0008-5472.CAN-04-3314. PMID: 15781663.Mitsutake N., Knauf J. A., Mitsutake S. et al. Conditional BRAFV600E expression induced DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 2005;65:2465–73. DOI: 10.1158/0008-5472.CAN-04-3314. PMID: 15781663.26. Salvatore G., DeFalco V., Salerno P. et al. BRAF is therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12:1623–9. DOI: 10.1158/1078–0432.CCR-05-2378. PMID: 16533790.Salvatore G., DeFalco V., Salerno P. et al. BRAF is therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12:1623–9. DOI: 10.1158/1078–0432.CCR-05-2378. PMID: 16533790.27. Espinosa A., Porchia L., Ringel M. Targeting BRAF in thyroid cancer. Br J Cancer 2007;96:16–20. DOI: 10.1038/sj.bjc.6603520. PMID: 17179987.Espinosa A., Porchia L., Ringel M. Targeting BRAF in thyroid cancer. Br J Cancer 2007;96:16–20. DOI: 10.1038/sj.bjc.6603520. PMID: 17179987.28. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245–62. DOI: 10.1677/erc.1.0978. PMID: 15947100.Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245–62. DOI: 10.1677/erc.1.0978. PMID: 15947100.29. Polverino A., Coxon A., Starnes C. et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006;66(17):8715–21. DOI: 10.1158/0008-5472.CAN-05-4665. PMID: 16951187.Polverino A., Coxon A., Starnes C. et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006;66(17):8715–21. DOI: 10.1158/0008-5472.CAN-05-4665. PMID: 16951187.30. Coxon A., Bready J., Fiorino M. et al. Anti-tumor activity of AMG 706, an oral multi-kinase inhibitor, in human medullary thyroid carcinoma xenografts. Thyroid 2006;16:920.Coxon A., Bready J., Fiorino M. et al. Anti-tumor activity of AMG 706, an oral multi-kinase inhibitor, in human medullary thyroid carcinoma xenografts. Thyroid 2006;16:920.31. Gruber J. J., Colevas A. D. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist 2015;20(2):113–26. DOI: 10.1634/theoncologist.2014-0313. PMCID: PMC4319630.Gruber J. J., Colevas A. D. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist 2015;20(2):113–26. DOI: 10.1634/theoncologist.2014-0313. PMCID: PMC4319630.32. Rosen L. S., Kurzrock R., Mulay M. et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:2369–76. DOI: 10.1200/JCO.2006.07.8170. PMID: 17557949.Rosen L. S., Kurzrock R., Mulay M. et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:2369–76. DOI: 10.1200/JCO.2006.07.8170. PMID: 17557949.33. Bass M. B., Davis M. T., Kivman L. et al. Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small cell lung cancer, and locally recurrent or advanced metastatic breast cancer. J Clin Oncol (Meeting Abstracts) 2010;28(Suppl):3037. DOI: 10.1210/jc.2010-0947. PMID: 20739388.Bass M. B., Davis M. T., Kivman L. et al. Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small cell lung cancer, and locally recurrent or advanced metastatic breast cancer. J Clin Oncol (Meeting Abstracts) 2010;28(Suppl):3037. DOI: 10.1210/jc.2010-0947. PMID: 20739388.34. Shoup M., Stojadinovic A., Nissan A. et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003;197(2):191–7. DOI: 10.1016/S1072-7515(03)00332-6. PMID: 12892796.Shoup M., Stojadinovic A., Nissan A. et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003;197(2):191–7. DOI: 10.1016/S1072-7515(03)00332-6. PMID: 12892796.35. Sala E., Mologni L., Truffa S. et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008;6:751–9. DOI: 10.1158/1541-7786.MCR-07-2001. PMID: 18458053.Sala E., Mologni L., Truffa S. et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008;6:751–9. DOI: 10.1158/1541-7786.MCR-07-2001. PMID: 18458053.36. Flaherty K., Puzanov I., Sosman J. et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol (Meeting Abstracts) 2009;27(Suppl):9000.Flaherty K., Puzanov I., Sosman J. et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol (Meeting Abstracts) 2009;27(Suppl):9000.37. Schwartz G. K., Robertson S., Shen A. A. Phase I study of XL281, a selective oral RAF kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2009;27(Suppl):3513. DOI: 10.1007/s10637-014-0191-5. PMID: 25476894.Schwartz G. K., Robertson S., Shen A. A. Phase I study of XL281, a selective oral RAF kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2009;27(Suppl):3513. DOI: 10.1007/s10637-014-0191-5. PMID: 25476894.38. Schlumberger M., Tahara M., Wirth L. J. et al. Lenvantinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. N Engl J Med 2015:72(7):621–30. DOI: 10.1056/NEJMoa1406470. PMID: 25671254.Schlumberger M., Tahara M., Wirth L. J. et al. Lenvantinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. N Engl J Med 2015:72(7):621–30. DOI: 10.1056/NEJMoa1406470. PMID: 25671254.39. Cohen E. E., Rosen L. S., Vokes E. E. et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708–13. DOI: 10.1200/JCO.2007.15.9566. PMID: 18541897.Cohen E. E., Rosen L. S., Vokes E. E. et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708–13. DOI: 10.1200/JCO.2007.15.9566. PMID: 18541897.40. Bocci G., Man S., Green S. K. et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res 2004;64:6616–25. DOI: 10.1158/0008-5472.CAN-04-0401. PMID: 15374976.Bocci G., Man S., Green S. K. et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res 2004;64:6616–25. DOI: 10.1158/0008-5472.CAN-04-0401. PMID: 15374976.41. Kumar R., Knick V.B., Rudolph S.K. et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012–21. DOI: 10.1158/1535-7163.MCT-07-0193. PMID: 17620431.Kumar R., Knick V.B., Rudolph S.K. et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012–21. DOI: 10.1158/1535-7163.MCT-07-0193. PMID: 17620431.42. Bible K.C., Smallridge R.C., Maples W.J. et al. Phase II trial of pazopanib in progressive,metastatic, iodineinsensitive differentiated thyroid cancers. J Clin Oncol (Meeting Abstracts) 2009; 27(Suppl):3521.Bible K.C., Smallridge R.C., Maples W.J. et al. Phase II trial of pazopanib in progressive,metastatic, iodineinsensitive differentiated thyroid cancers. J Clin Oncol (Meeting Abstracts) 2009; 27(Suppl):3521.43. Kim D. W., Jo Y. S., Jung H. S. et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:4070–6. DOI: 10.1210/jc.2005-2845. PMID: 16849418.Kim D. W., Jo Y. S., Jung H. S. et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:4070–6. DOI: 10.1210/jc.2005-2845. PMID: 16849418.44. Dawson S. J., Conus N. M., Toner G. C. et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 2008;19:547–52.Dawson S. J., Conus N. M., Toner G. C. et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 2008;19:547–52.45. Ravaud A., de la Fouchardi’re C., Courbon F. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. 2008 [cited 15 December 2008]; available at: http://www.asco.org/ASCO/Meeting/Abstracts&vmview.abst_detail_ view&confID.55&abstractID=33144.Ravaud A., de la Fouchardi’re C., Courbon F. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. 2008 [cited 15 December 2008]; available at: http://www.asco.org/ASCO/Meeting/Abstracts&vmview.abst_detail_ view&confID.55&abstractID=33144.46. Wedge S. R., Ogilvie D. J., Dukes M. et al. ZD6474 inhibits vascular endothelian growth factor signalling angiogenesis, and tumor growth following oral administration. Cancer Research 2002;62:4645–55. PMID: 12183421.Wedge S. R., Ogilvie D. J., Dukes M. et al. ZD6474 inhibits vascular endothelian growth factor signalling angiogenesis, and tumor growth following oral administration. Cancer Research 2002;62:4645–55. PMID: 12183421.47. Nikiforova M. N., Kimura E. T., Gandhi M. et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399–404. DOI: 10.1210/jc.2003-030838. PMID: 14602780.Nikiforova M. N., Kimura E. T., Gandhi M. et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399–404. DOI: 10.1210/jc.2003-030838. PMID: 14602780.48. Leboulleux S., Bastholt L., Krause T. et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13:897–905. DOI: 10.1016/S1470-2045(12)70335–2. PMID: 22898678.Leboulleux S., Bastholt L., Krause T. et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13:897–905. DOI: 10.1016/S1470-2045(12)70335–2. PMID: 22898678.49. Garcia-Rostan G., Zhao H., Camp R. L. et al. Ras mutation are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003;21:3226–35. PubMed Abstract | Publisher Full Text. DOI: 10.1200/JCO.2003.10.130. PMID: 12947056.Garcia-Rostan G., Zhao H., Camp R. L. et al. Ras mutation are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003;21:3226–35. PubMed Abstract | Publisher Full Text. DOI: 10.1200/JCO.2003.10.130. PMID: 12947056.50. Ricarte-Filho J. C., Ryder M., Chitale D. A. et al. Mutational profile of advanced primary and metastatic radioactive iodinerefractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009;69(11):4885–93. DOI: 10.1158/0008-5472.CAN-09-0727. PMID: 19487299.Ricarte-Filho J. C., Ryder M., Chitale D. A. et al. Mutational profile of advanced primary and metastatic radioactive iodinerefractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009;69(11):4885–93. DOI: 10.1158/0008-5472.CAN-09-0727. PMID: 19487299.51. Wilhelm S. M., Carter C., Tang L. Y. et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099–109. DOI: 10.1158/0008-5472.CAN-04-1443. PMID: 15466206.Wilhelm S. M., Carter C., Tang L. Y. et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099–109. DOI: 10.1158/0008-5472.CAN-04-1443. PMID: 15466206.52. Wells S. A., Nevins J. R. Evolving strategies for targeted cancer therapy past, present, and future. J Natl cancer Inst 2004;96:980–1. PMID: 15240773.Wells S. A., Nevins J. R. Evolving strategies for targeted cancer therapy past, present, and future. J Natl cancer Inst 2004;96:980–1. PMID: 15240773.53. Plaza-Menacho I., Mologni L., Sala E. et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 2007;282:29230–40. DOI: 10.1074/jbc.M703461200. PMID: 17664273.Plaza-Menacho I., Mologni L., Sala E. et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 2007;282:29230–40. DOI: 10.1074/jbc.M703461200. PMID: 17664273.54. Salvatore G., De Falco V., Salerno P. et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12:1623–9. DOI: 10.1158/1078-0432.CCR-05-2378. PMID: 16533790.Salvatore G., De Falco V., Salerno P. et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12:1623–9. DOI: 10.1158/1078-0432.CCR-05-2378. PMID: 16533790.55. Carlomagno F., Guida T., Anaganti S. et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase conferresistance to selective kinase inhibitors. Oncogene 2004;23:6056–63. DOI: 10.1038/sj.onc.1207810. PMID: 15184865.Carlomagno F., Guida T., Anaganti S. et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase conferresistance to selective kinase inhibitors. Oncogene 2004;23:6056–63. DOI: 10.1038/sj.onc.1207810. PMID: 15184865.56. Brose M. S., Troxel A. B., Harlacker K. Completion of a phase II study of sorafenib for advanced thyroid cancer [abstract].Eur J Cancer Suppl 2009;7:22.Brose M. S., Troxel A. B., Harlacker K. Completion of a phase II study of sorafenib for advanced thyroid cancer [abstract].Eur J Cancer Suppl 2009;7:22.57. Gupta-Abramson V., Troxel A. B., Nellore A: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714–9. DOI: 10.1200/JCO.2008.16.3279. PMID: 18541894.Gupta-Abramson V., Troxel A. B., Nellore A: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714–9. DOI: 10.1200/JCO.2008.16.3279. PMID: 18541894.58. Kloos R. T., Ringel M. D., Knopp M. V. et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27:1675–84. DOI: 10.1200/JCO.2008.18.2717. PMCID: PMC2668972.Kloos R. T., Ringel M. D., Knopp M. V. et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27:1675–84. DOI: 10.1200/JCO.2008.18.2717. PMCID: PMC2668972.59. Ahmed M., Barbachano Y., Riddell A. M. Preliminary results of an open labelled phase 2 study evaluating the safety and efficacy of sorafenib in metastatic advanced thyroid cancer [abstract]. J Clin Oncol 2008;26:6060.Ahmed M., Barbachano Y., Riddell A. M. Preliminary results of an open labelled phase 2 study evaluating the safety and efficacy of sorafenib in metastatic advanced thyroid cancer [abstract]. J Clin Oncol 2008;26:6060.60. Румянцев П. О. Рефрактерность высокодифференцированного рака щитовидной железы к лечению радиоактивным йодом. Опухоли головы и шеи 2013;3:11–15. [Rumyantsev P. O. Refractory of well-differentiated thyroid cancer to the treatment with radioactive iodin. Opukholigolovy i shei = Head and Neck Tumors 2013;3:11–15. (In Russ.)]. DOI: 10.17650/2222-1468-2013-0-3-11-15.Румянцев П. О. Рефрактерность высокодифференцированного рака щитовидной железы к лечению радиоактивным йодом. Опухоли головы и шеи 2013;3:11–15. [Rumyantsev P. O. Refractory of well-differentiated thyroid cancer to the treatment with radioactive iodin. Opukholigolovy i shei = Head and Neck Tumors 2013;3:11–15. (In Russ.)]. DOI: 10.17650/2222-1468-2013-0-3-11-15.61. Brose M., Nutting C. M., Sherman S. I. et al. Rationale and design of decision: a doublе-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI) – refractory, differentiated thyroid cancer. BMC Cancer 2011;11:349–70. DOI: 10.1186/1471-2407-11-349. PMID: 21834960.Brose M., Nutting C. M., Sherman S. I. et al. Rationale and design of decision: a doublе-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI) – refractory, differentiated thyroid cancer. BMC Cancer 2011;11:349–70. DOI: 10.1186/1471-2407-11-349. PMID: 21834960.62. Brose M. S., Nutting C. M., Jarzab B. et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. Presented at ASCO 2013. J Clin Oncol 2013;31:2(suppl): Abstract 4. DOI: 10.1016/S0140-6736(14)60421-9. PMID: 24768112.Brose M. S., Nutting C. M., Jarzab B. et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. Presented at ASCO 2013. J Clin Oncol 2013;31:2(suppl): Abstract 4. DOI: 10.1016/S0140-6736(14)60421-9. PMID: 24768112.63. Резолюция экспертного совета по вопросам таргетной терапии дифференцированного рака щитовидной железы, резистентного к терапии радио активным йодом. Опухоли головы и шеи 2014;3:10–11. [The resolution of the expert council for targeted therapy of radioiodine refractory differentiated thyroid cancer. Opukholigolovy i shei = Head and Neck Tumors 2014;3:10–11. (In Russ.)].Резолюция экспертного совета по вопросам таргетной терапии дифференцированного рака щитовидной железы, резистентного к терапии радио активным йодом. Опухоли головы и шеи 2014;3:10–11. [The resolution of the expert council for targeted therapy of radioiodine refractory differentiated thyroid cancer. Opukholigolovy i shei = Head and Neck Tumors 2014;3:10–11. (In Russ.)].